Clinicians now have a new first-line therapy that may significantly improve care for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). On … Continue reading Alectinib Approved as First-Line Therapy for ALK-Positive Metastatic NSCLC